FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA)

G. Baranello (London, United Kingdom), L. Servais (Oxford, United Kingdom), R. Masson (Milan, Italy), M. Mazurkiewicz-Beldzinska (Gdansk, Poland), K. Rose (Sydney, Australia), D. Vlodavets (Moscow, Russian Federation), H. Xiong (Beijing, China), E. Zanoteli (São Paulo, Brazil), M. El-Khairi (Welwyn Garden City, United Kingdom), S. Fuerst-Recktenwald (Basel, Switzerland), M. Gerber (Basel, Switzerland), K. Gorni (Basel, Switzerland), H. Kletzl (Basel, Switzerland), R. Scalco (Basel, Switzerland), B. Darras (Boston, MA, United States of America)

Source: Virtual Congress 2020 – Respiratory physiology and sleep: new approaches to diagnosis and treatment
Session: Respiratory physiology and sleep: new approaches to diagnosis and treatment
Session type: E-poster session
Number: 1172
Disease area: Paediatric lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Baranello (London, United Kingdom), L. Servais (Oxford, United Kingdom), R. Masson (Milan, Italy), M. Mazurkiewicz-Beldzinska (Gdansk, Poland), K. Rose (Sydney, Australia), D. Vlodavets (Moscow, Russian Federation), H. Xiong (Beijing, China), E. Zanoteli (São Paulo, Brazil), M. El-Khairi (Welwyn Garden City, United Kingdom), S. Fuerst-Recktenwald (Basel, Switzerland), M. Gerber (Basel, Switzerland), K. Gorni (Basel, Switzerland), H. Kletzl (Basel, Switzerland), R. Scalco (Basel, Switzerland), B. Darras (Boston, MA, United States of America). FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA). 1172

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: